FI3347002T3 - Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa - Google Patents
Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa Download PDFInfo
- Publication number
- FI3347002T3 FI3347002T3 FIEP16845181.3T FI16845181T FI3347002T3 FI 3347002 T3 FI3347002 T3 FI 3347002T3 FI 16845181 T FI16845181 T FI 16845181T FI 3347002 T3 FI3347002 T3 FI 3347002T3
- Authority
- FI
- Finland
- Prior art keywords
- subject
- pharmaceutical composition
- treatment
- use according
- valyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216404P | 2015-09-10 | 2015-09-10 | |
| US201662290287P | 2016-02-02 | 2016-02-02 | |
| US201662302027P | 2016-03-01 | 2016-03-01 | |
| US201662365809P | 2016-07-22 | 2016-07-22 | |
| PCT/US2016/051091 WO2017044840A1 (en) | 2015-09-10 | 2016-09-09 | Methods of treating neurodegenerative disorders in a particular patient population |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3347002T3 true FI3347002T3 (fi) | 2023-08-10 |
Family
ID=58240195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16845181.3T FI3347002T3 (fi) | 2015-09-10 | 2016-09-09 | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11191742B2 (enExample) |
| EP (2) | EP4275750A3 (enExample) |
| JP (4) | JP6789579B2 (enExample) |
| KR (2) | KR102412997B1 (enExample) |
| CN (3) | CN108289870A (enExample) |
| AU (1) | AU2016319107B2 (enExample) |
| CA (1) | CA2997376C (enExample) |
| DK (1) | DK3347002T3 (enExample) |
| ES (1) | ES2952727T3 (enExample) |
| FI (1) | FI3347002T3 (enExample) |
| HR (1) | HRP20230809T1 (enExample) |
| HU (1) | HUE062511T2 (enExample) |
| LT (1) | LT3347002T (enExample) |
| MD (1) | MD3347002T2 (enExample) |
| MX (2) | MX392677B (enExample) |
| PL (1) | PL3347002T3 (enExample) |
| PT (1) | PT3347002T (enExample) |
| RS (1) | RS64481B1 (enExample) |
| SI (1) | SI3347002T1 (enExample) |
| SM (1) | SMT202300250T1 (enExample) |
| WO (1) | WO2017044840A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015230972B2 (en) | 2014-03-21 | 2021-05-27 | Alzheon, Inc. | Methods for treating neurological disorders |
| WO2017044840A1 (en) * | 2015-09-10 | 2017-03-16 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular patient population |
| CN114805211B (zh) | 2017-03-21 | 2024-08-23 | 润佳（苏州）医药科技有限公司 | 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途 |
| CN110003058B (zh) | 2018-01-04 | 2022-01-25 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途 |
| PL3829568T3 (pl) * | 2018-08-01 | 2024-03-25 | Alzheon, Inc. | Pochodne kwasu sulfopropanowego do leczenia zaburzeń neurodegeneracyjnych |
| LT3829563T (lt) * | 2018-08-01 | 2025-02-25 | Alzheon, Inc. | 3-sulfopropano rūgštis neurodegeneracinėms ligoms gydyti |
| CN111170901A (zh) * | 2018-11-13 | 2020-05-19 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途 |
| CN114269949A (zh) | 2019-06-17 | 2022-04-01 | 阿尔泽恩股份有限公司 | 用于治疗神经变性病症的方法 |
| CN112791078B (zh) | 2019-11-13 | 2022-12-06 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| MX2024007070A (es) * | 2021-12-09 | 2024-08-22 | Alzheon Inc | Alz-801 para uso en el tratamiento de la enfermedad de alzheimer. |
| US20250127734A1 (en) * | 2022-02-07 | 2025-04-24 | Alzheon, Inc. | Alz-801 for use in treating a covid-19 associated neurological symptom |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| WO1994009155A1 (en) | 1992-10-13 | 1994-04-28 | Duke University | Methods of detecting alzheimer's disease |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20060079578A1 (en) | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| WO2005060393A2 (en) | 2003-08-11 | 2005-07-07 | California Institute Of Technology | Microfluidic large scale integration |
| JP2008535907A (ja) * | 2005-04-12 | 2008-09-04 | ニユーロケム（インターナショナル）、リミテッド | アミロイド阻害化合物の薬学的製剤 |
| EP2862581B1 (en) | 2006-10-12 | 2021-08-11 | BHI Limited Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| US20100183513A1 (en) | 2006-11-24 | 2010-07-22 | Wolfgang Froestl | N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US20120009125A1 (en) | 2010-07-06 | 2012-01-12 | Lombard Jay L | Apoe4 and apoj biomarker-based prevention and treatment of dementia |
| DK2605655T3 (en) * | 2010-08-19 | 2019-02-04 | Buck Institute For Age Res | METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS |
| WO2013168174A1 (en) * | 2012-05-08 | 2013-11-14 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| JP6424210B2 (ja) * | 2013-05-06 | 2018-11-14 | バクスアルタ インコーポレイテッド | プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療 |
| BR112016018170A2 (pt) | 2014-02-08 | 2018-02-20 | Genentech, Inc. | métodos para tratar doença de alzheimer |
| AU2015230972B2 (en) | 2014-03-21 | 2021-05-27 | Alzheon, Inc. | Methods for treating neurological disorders |
| WO2017044840A1 (en) * | 2015-09-10 | 2017-03-16 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular patient population |
-
2016
- 2016-09-09 WO PCT/US2016/051091 patent/WO2017044840A1/en not_active Ceased
- 2016-09-09 CN CN201680052760.4A patent/CN108289870A/zh active Pending
- 2016-09-09 JP JP2018512564A patent/JP6789579B2/ja active Active
- 2016-09-09 HU HUE16845181A patent/HUE062511T2/hu unknown
- 2016-09-09 SI SI201631729T patent/SI3347002T1/sl unknown
- 2016-09-09 AU AU2016319107A patent/AU2016319107B2/en active Active
- 2016-09-09 HR HRP20230809TT patent/HRP20230809T1/hr unknown
- 2016-09-09 PL PL16845181.3T patent/PL3347002T3/pl unknown
- 2016-09-09 MX MX2018003023A patent/MX392677B/es unknown
- 2016-09-09 RS RS20230603A patent/RS64481B1/sr unknown
- 2016-09-09 LT LTEPPCT/US2016/051091T patent/LT3347002T/lt unknown
- 2016-09-09 EP EP23176559.5A patent/EP4275750A3/en active Pending
- 2016-09-09 EP EP16845181.3A patent/EP3347002B1/en active Active
- 2016-09-09 SM SM20230250T patent/SMT202300250T1/it unknown
- 2016-09-09 KR KR1020187009381A patent/KR102412997B1/ko active Active
- 2016-09-09 KR KR1020227009418A patent/KR102547164B1/ko active Active
- 2016-09-09 ES ES16845181T patent/ES2952727T3/es active Active
- 2016-09-09 CA CA2997376A patent/CA2997376C/en active Active
- 2016-09-09 CN CN202310582394.5A patent/CN116712423A/zh active Pending
- 2016-09-09 CN CN202310582365.9A patent/CN116712422A/zh active Pending
- 2016-09-09 MD MDE20180700T patent/MD3347002T2/ro unknown
- 2016-09-09 DK DK16845181.3T patent/DK3347002T3/da active
- 2016-09-09 PT PT168451813T patent/PT3347002T/pt unknown
- 2016-09-09 FI FIEP16845181.3T patent/FI3347002T3/fi active
- 2016-09-09 US US15/758,405 patent/US11191742B2/en active Active
-
2018
- 2018-03-09 MX MX2022003128A patent/MX2022003128A/es unknown
-
2020
- 2020-09-28 JP JP2020161995A patent/JP7128536B2/ja active Active
-
2021
- 2021-09-17 US US17/477,886 patent/US20220096406A1/en not_active Abandoned
-
2022
- 2022-08-12 JP JP2022128786A patent/JP2022145949A/ja active Pending
-
2023
- 2023-09-06 US US18/462,238 patent/US20230414541A1/en active Pending
-
2025
- 2025-02-17 JP JP2025023627A patent/JP2025065545A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3347002T3 (fi) | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa | |
| Ge et al. | Zinc attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury by activating Nrf2/GPX4 defense pathway | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| CY1117667T1 (el) | 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης | |
| Moslemi et al. | Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: a double blind, randomized controlled clinical trial | |
| NZ602777A (en) | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | |
| JP2018526407A5 (enExample) | ||
| EP3094322B1 (en) | Administration of tasimelteon under fasted conditions | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| MX2015016527A (es) | Polimeros enlazados al proton para administracion oral. | |
| Narver | Nalbuphine, a non-controlled opioid analgesic, and its potential use in research mice | |
| FI3478712T3 (fi) | Anti-N3pGlu beeta-amyloidipeptidi -vasta-aineita ja niiden käyttöjä | |
| JP2015519329A5 (enExample) | ||
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| US20230310488A1 (en) | Compositions and methods that attenuate cognitive aging in individuals who do not have dementia | |
| WO2012044783A8 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| CN106038522B (zh) | 大黄酸在制备抗抑郁症药物中的用途 | |
| CN104622874B (zh) | Ccr4拮抗剂在抑制癌生长及转移中的应用 | |
| CN104906501B (zh) | 治疗银屑病的中药组分组合物 | |
| BR102022010274A2 (pt) | Composição de aciletanolamidas a partir de ácidos graxos de azeite de oliva |